Twist Bioscience (NASDAQ:TWST) Shares Up 8.9% – Time to Buy?

Posted by Brenda Bartman on Sep 26th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) shares were up 8.9% during mid-day trading on Thursday. The stock traded as high as $166.96 and last traded at $172.6130. 175,939 shares changed hands during trading, a decline of 89% from the average daily volume of 1,555,326 shares. The stock had previously closed at $158.50.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TWST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday. UBS Group began coverage on shares of Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price for the company. Piper Sandler upped their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. BWS Financial restated a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a research note on Friday, September 18th. Finally, Leerink Partners lifted their price target on Twist Bioscience from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Thursday, September 17th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $103.00.

Check Out Our Latest Report on Twist Bioscience

Twist Bioscience Trading Down 0.7%

The stock has a market capitalization of $11.47 billion, a P/E ratio of -82.36 and a beta of 2.22. The business has a 50 day simple moving average of $126.89 and a 200-day simple moving average of $87.13. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same period in the prior year, the firm posted $0.33 EPS. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. On average, analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 2,399 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the completion of the sale, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. This represents a 2.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 294 shares of the firm’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $165.49, for a total transaction of $48,654.06. Following the transaction, the senior vice president owned 116,720 shares of the company’s stock, valued at approximately $19,315,992.80. This trade represents a 0.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 521,777 shares of company stock valued at $78,416,543 in the last ninety days. 3.08% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TWST. Allworth Financial LP acquired a new stake in shares of Twist Bioscience during the 2nd quarter valued at $62,000. Trifecta Capital Advisors LLC acquired a new position in shares of Twist Bioscience in the 2nd quarter worth $63,000. Western Wealth Management LLC acquired a new position in shares of Twist Bioscience in the 1st quarter worth $31,000. Strs Ohio acquired a new stake in shares of Twist Bioscience during the first quarter worth $33,000. Finally, GAMMA Investing LLC raised its position in shares of Twist Bioscience by 24.4% during the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after purchasing an additional 185 shares during the period.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.